219 related articles for article (PubMed ID: 2459005)
1. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Kaiser B; Hauptmann J; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological studies on the low molecular weight heparin derivative CY 216.
Kaiser B; Kühnemuth G; Markwardt F
Pharmazie; 1990 Jul; 45(7):522-4. PubMed ID: 2173004
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.
Diness V; Nielsen JI; Pedersen PC; Wolffbrandt KH; Ostergaard PB
Thromb Haemost; 1986 Jun; 55(3):410-4. PubMed ID: 3750271
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Kaiser B; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin.
Holst J; Lindblad B; Bergqvist D; Nordfang O; Ostergaard PB; Petersen JG; Nielsen G; Hedner U
Thromb Haemost; 1994 Feb; 71(2):214-9. PubMed ID: 8191401
[TBL] [Abstract][Full Text] [Related]
6. Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis.
Carelli G; Maffei FH; Mattar L; Ferrari IC; Thomazini-Santos IA; de Carvalho LR
Pathophysiol Haemost Thromb; 2005; 34(6):263-8. PubMed ID: 16772737
[TBL] [Abstract][Full Text] [Related]
7. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
8. Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models.
Hauptmann J; Barth A; Schönberger FP; Markwardt F
Biomed Biochim Acta; 1983; 42(7-8):959-65. PubMed ID: 6651812
[TBL] [Abstract][Full Text] [Related]
9. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Eriksson BI; Carlsson S; Halvarsson M; Risberg B; Mattsson C
Thromb Haemost; 1997 Nov; 78(5):1404-7. PubMed ID: 9408027
[TBL] [Abstract][Full Text] [Related]
11. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic and anticoagulant properties of synthetic polyanions: sulfated bis-aldonic acid amides.
Klauser RJ; Raake W; Meinetsberger E; Zeiller P
J Pharmacol Exp Ther; 1991 Oct; 259(1):8-14. PubMed ID: 1656031
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
14. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
Fonseca RJ; Mourão PA
Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
[TBL] [Abstract][Full Text] [Related]
15. The effect of taurolidine on experimental thrombus formation.
Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F
Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects.
Saivin S; Petitou M; Lormeau JC; Dupouy D; Sie P; Caranobe C; Houin G; Boneu B
J Lab Clin Med; 1992 Feb; 119(2):189-96. PubMed ID: 1740633
[TBL] [Abstract][Full Text] [Related]
18. A new model to assess the haemorrhagic potential of various heparin preparations.
Berstad A; Bang CJ; Talstad I
Acta Chir Scand Suppl; 1990; 556():62-7. PubMed ID: 1963019
[TBL] [Abstract][Full Text] [Related]
19. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
Farias WR; Nazareth RA; Mourão PA
Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
[TBL] [Abstract][Full Text] [Related]
20. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
